StemCell Therapy

October is Breast Cancer Awareness Month. In some ways, the month is a celebration of the many advances made toward diagnosing and treating breast cancer at its very earliest stages. With these earlier identifications come the expectations for more favorable treatment and survival outcomes.

That said, when a cancer diagnosis is delivered, the individual receiving it often hears nothing but I have cancer. Words like these can be overwhelming. It begins a search to gather and develop the most competent team to lead you through this journey.

There are many options when considering breast cancer surgery. Those are for you and your surgical team to examine. Perhaps you have chosen to pursue a lumpectomy or a mastectomy. These procedures might include lymph nodes being removed in the axilla (the armpit), to discover if a cancer has spread elsewhere.

But what happens after a tumor has been removed? Surgical intervention can deliver a whole new set of concerns including:

n Tissue adhesions that can lead to postural changes

n Impaired shoulder function

n Pain and subsequent movement compensations

n Seromas

n Hematomas

n Serratus anterior weakness

n Axillary web syndrome/cording (scarring or connective tissue under the arm that can limit range of motion)

Lymphedema is also a common side effect following breast cancer surgery. It occurs after the lymph nodes have been removed or damaged, impairing normal lymphatic flow in the arm, which causes the arm to swell.

Your plan of care might also include radiation or chemotherapy. If radiation is part of your treatment, there can be temporary tissue adhesions; reduced shoulder and trunk range of motion; inflammatory edema (swelling caused by excess fluid); and pain. You may also experience permanent changes called radiation fibrosis, which is scar tissue that can occur in the breast and chest wall.

If your oncology team decides chemotherapy is warranted, challenges from the treatment can include pain; fatigue; poor tolerance to activity; neuropathy; weakness; and an increased risk of cardiovascular disease.

Regardless of your breast cancer treatment approach, every survivors plan for recovery should include treatment for whatever physical changes you may experience. It is imperative to see a physical therapist and certified lymphedema therapist early on to ensure the best results.

A therapist trained in breast cancer rehabilitation can work with you to:

n Address shoulder, complex movement, and soft tissue disorders

n Improve your comfort and function during and following breast reconstruction

n Address effects of radiation

n Reduce fatigue and weakness

n Develop an individualized home exercise program

St. Peters Health Partners Patient Therapies has a variety of outpatient physical therapists at locations throughout the Capital District, accepting all insurances and providing quality one-on-one treatment. Our staff works closely with your oncology and/or primary care team to help decrease pain, improve flexibility, and reduce effects of scar tissue adhesions/radiation fibrosis.

If you are seeking treatment for lymphedema, our therapists have received specialized training in manual lymph drainage and compression bandaging. We have the longest operating lymphedema management program in the Capital District.

For information, call 518-268-5749 or visit us at http://www.sphp.com/patient-therapies.

See more here:

Surviving breast cancer what comes next? - Hudson Valley 360

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global diabetic neuropathy drugs market since 2016 and the market is poised to grow by USD 866.72 million during 2019-2023, progressing at a CAGR of about 6% during the forecast period. Request Free Sample Pages

Read the 135-page research report with TOC on "Diabetic Neuropathy Drugs Market Analysis Report by Mechanism of action (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023."

The market is driven by the approval of new drugs and the presence of a strong drug pipeline. In addition, the development of novel biologics to treat diabetic neuropathy is anticipated to further boost the growth of the diabetic neuropathy drugs market.

Market vendors are increasingly focusing on the development of disease-modifying drugs to treat diabetic neuropathy due to its growing prevalence. The market is witnessing an increase in the number of approvals of drugs such as LYRICA CR extended-release tablets. These drugs are used to manage neuropathic pain associated with diabetic peripheral neuropathy. In addition, there are several drugs that are in the last-stages of the pipeline. VM202 is an investigational therapy that is currently in Phase III clinical trials. Thus, approval of such new drugs and the presence of a strong drug pipeline is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for FREE.

View market snapshot before purchasing

Major Five Diabetic Neuropathy Drugs Market Companies:

Pfizer Inc.

Pfizer Inc. is headquartered in the US and owns and operates businesses under various segments such as innovative health and essential health. The company offers LYRICA and NEURONTIN. LYRICA is used to treat diabetic nerve pain.

Novartis AG

Novartis AG is headquartered in Switzerland and manufactures products through several business segments such as innovative medicines, sandoz, and alcon. The company offers Tegretol, which is an anticonvulsant medication used in the treatment of neuropathic pain.

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc. is headquartered in the US and has business operations under various segments, namely pharmaceutical, medical devices, and consumer. The company offers NUCYNTA, which is an opioid analgesic used to treat diabetic neuropathy pain.

Eli Lilly and Company

Eli Lilly and Company is headquartered in the US and offers products through business segments such as human pharmaceutical products and animal health products. The company offers CYMBALTA, which is used to treat neuropathic pain.

DAIICHI SANKYO COMPANY, LIMITED

DAIICHI SANKYO COMPANY, LIMITED is headquartered in Japan and offers products through business segments such as innovative pharmaceuticals business and generic business. The company offers Tarlige, which is used to treat peripheral neuropathic pain.

Register for a free trial today and gain instant access to 10,000+ market research reports. Technavio's SUBSCRIPTION platform

Diabetic Neuropathy Drugs Mechanism of Action Outlook (Revenue, USD Million, 2019 - 2023)

Diabetic Neuropathy Drugs Regional Outlook (Revenue, USD Million, 2019 - 2023)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care are:

Pericarditis Drugs Market Global Pericarditis Drugs Market by product (NSAIDs, colchicine, and others) and geography (Asia, Europe, North America, and ROW).

Blepharitis Drugs Market Global Blepharitis Drugs Market by product (steroids and antibiotics) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Continued here:

Diabetic Neuropathy Drugs Market 2019-2023 | Evolving Opportunities with Pfizer Inc. and Novartis AG | Technavio - Business Wire

Anxiety is a common response to an increasingly demanding society and work culture. We are surrounded by physical and mental stressors that may impact the body in ways that mirror peripheral neuropathy symptoms.

For caregivers and patients suffering from familial amyloid polyneuropathy, it is important to be aware of how stress affects peripheral neuropathy symptoms and to distinguish the differences in bodily reactions to these stressors.

The symptoms of stress may be similar to those of peripheral neuropathy. That includes the constricting of blood vessels due to hyperventilation and seemingly hyperactive nerve activity.

Patients who are prone to anxiety attacks must be aware of how their hands, feet, and arms are feeling. The constriction of blood cells caused by hyperventilation may increase tingling and burning sensations in the peripheral nerves. Patients and caregivers should be aware of how reduced blood flow due to hyperventilation may impact existing peripheral neuropathy symptoms.

Anxiety may also cause increased nerve reactions in the body. The increase in nerve firings may cause cramps and symptoms similar to nerve damage. As these symptoms may feel similar to those caused by peripheral neuropathy, caregivers and patients must be diligent in having both topical treatments and stress-relieving exercises readily available.

Breathing exercises may help patients relax during times of increased stress. During hyperventilation, patients should breathe in deeply, holding each breath for a few seconds and then slowly breathing out for seven to 10 seconds. This exercise helps patients relax their bodies and may help to reduce the effects of hyperventilation caused by anxiety.

Spending time with loved ones helps patients distract themselves from stressors that may cause anxiety. Being around people whose company a patient enjoys may help increase feelings of happiness. Activities may include spending time with children, traveling with family, or spending holidays together.

My mother-in-laws preferred method of battling anxiety and depression is by spending time with her loved ones. She is rooted in her family. The time spent with them provides her with a sense of purpose and a distraction from her bodily pains. They are her support center when she needs it.

Massage therapy may help patients relax their bodies and reduce the impact of peripheral neuropathy symptoms. Relaxing the body is an effective way to mitigate the effects of anxiety. When pursuing massage therapy, caregivers need to understand their patients thresholds for touch. Applied pressure may cause increased pain and essentially negate the desired outcome for massage therapy.

Massage therapy may include self-administered massages, professional massages, and foot massages. The ultimate goal for patients pursuing massage therapy for anxiety is to relax the body while providing a mental distraction that reduces the symptoms.

What are some ways that you reduce stress or anxiety? Please share in the comments below.

***

Note: FAP News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of FAP News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to familial amyloid polyneuropathy.

Sorry! The Author has not filled his profile.

See the original post:

How Caregivers and Patients Can Manage Bodily Responses to Stress - FAP News Today

LOS ANGELES--(BUSINESS WIRE)--There has recently been an increase in need for Pain Medicine Experts to perform Independent Medical Evaluations (IMEs) and act as Expert Witnesses in the San Francisco Bay Area. To fill the demand, California Medical Evaluators (CME) has added several pain medicine expert witnesses to its network of board-certified and highly competent doctors.

A Pain Medicine IME is performed by a board-certified pain medicine expert who uses his/her expertise to evaluate the physical condition of an individual who sustained an injury outside of the workplace. Pain Medicine Experts focus on the evaluation, treatment and prevention of pain. Conditions that pain medicine experts treat include chronic pain, arthritis, back and neck pain, fibromyalgia, neuropathic pain, and headaches.

One of the most common conditions treated by pain medicine experts is Complex Regional Pain Syndrome (CRPS), which is a condition that usually affects one limb, most often occurring after an injury. It is characterized by excessive or prolonged pain and changes in temperature, swelling and skin color in the affected area. CRPS is not easily identifiable, which makes it necessary to have a pain medicine expert evaluate any individual who believes he or she may suffer from the condition.

California Medical Evaluators has over 150 medical experts in all specialties available for IMEs and Expert Witness Testimony throughout the state of California. Dr. Joseph Sclafani and Dr. Mikiko Murakami are two of CMEs newest Pain Medicine Experts in the San Francisco Bay Area. Both are highly experienced with all types of spine, nerve, joint and muscle pain, including CRPS, cervical radiculopathy, rotator cuff tendonitis, low back issues, and peripheral neuropathy such as carpal tunnel syndrome.

For more information about California Medical Evaluators or to request a pain medicine expert, visit calmedeval.com.

About California Medical Evaluators

California Medical Evaluators (CME) is a leading provider of Med-Legal Practice Management services to physicians who perform Qualified Medical Examinations (QMEs), Independent Medical Examinations (IMEs) and medical expert witness engagements. CMEs broad network of qualified physician experts perform over 5,000 medical-legal examinations annually. Founded in 2010 by physicians, CME has become a leader in QME practice management, while also providing IME services, fitness for duty evaluations, and disability evaluations for the legal and insurance industries. More information about CME can be found at CalMedEval.com or by calling (888)-853-7944.

Read the rest here:

California Medical Evaluators Grows its Network of Pain Medicine Experts in the San Francisco Bay Area - Business Wire

Incidence of vincristine-induced neuropathy does not appear to be associated with nutritional deficiencies, according to research published in Pediatric Hematology and Oncology.

Vincristine, a vinca alkaloid chemotherapy drug, is commonly used in the treatment of childhood acute lymphoblastic leukemia (ALL) but can lead to chemotherapy-induced peripheral neuropathy, an important dose-limiting toxicity. However, little research has been conducted in patients with possible concomitant nutritional deficiencies.

Therefore, researchers conducted a prospective observational study over a period of 2 years at a childrens hospital in India. They evaluated 30 children with newly diagnosed ALL, 28 (93.3%) of whom had B-cell ALL and 2 (6.7%) of whom had T-cell ALL. Vitamin B12, folate, and serum ferritin levels were measured for all patients.

Over 4 weeks of observation, clinical peripheral neuropathy developed in 12 patients. Autonomic nervous system involvement was the most common, but involvement of the sensory and motor systems occurred as well. Electrophysiologic testing found that 15 patients (50%) had neuropathy.

Undernutrition, defined using criteria from the World Health Organization, was identified in 14 patients (46.7%). No difference was found in incidence of vincristine-induced neuropathy between patients with undernutrition (7 patients) and patients without undernutrition (8 patients). Additionally, the researchers found no correlation between presence of undernutrition and development of neuropathy (P =1.0). Levels of vitamin B12, folate, and serum ferritin were similar in children with and without neuropathy.

The researchers concluded that although optimal nerve function is dependent on a constant supply of macronutrients and micronutrients, nutritional deficiencies may not influence development of neuropathy in Indian children with ALL. However, they acknowledged that their study had some limitations, such as the inability to measure expression of CYP3A5 (an enzyme responsible for vincristine metabolism) and serum albumin and the use of ferritin to assess iron deficiency. They noted that further research is warranted to evaluate the role of micronutrient deficiencies in the development of vincristine-induced peripheral neuropathy in childhood ALL.

Reference

Dudeja S, Gupta S, Sharma S, et al. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies [published online September 13, 2019]. Pediatr Hematol Oncol.

This article originally appeared on Hematology Advisor

Go here to see the original:

No Link Between Nutritional Deficiencies, Vincristine-Induced Neuropathy in Pediatric Acute Lymphoblastic Leukemia - Cancer Therapy Advisor

Declines in global health status and quality of life, physical functioning, fatigue, and pain begin to appear 2 to 3 months before progression of the underlying malignant disease, multiple myeloma researchers said in a new study.

Whereas previous studies have focused on response rate, the quality of the response, progression-free survival (PFS), and overall survival (OS), increased attention is being paid to QOL issues, as patients live longer and there is a greater emphasis placed on shared decision making and a greater focus being placed on QOL data, noted the authors.

This median age of the 90 patients with relapsed/refractory MM in this study was 67 years; 41% were stage I, 33% were stage II, and 26% were stage III.

Researchers found significant impairment in health-related QOL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, compared with the general population. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant change in other categories. During maintenance treatment, health-related QOL, physical functioning, and pain improved, but neuropathy did not.

Time to deterioration (10 or more score points) of health-related QOL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QOL and physical functioning at baseline correlated with OS.

Previous studies have shown that physicians often underestimate the impact of cancer-associated symptoms such as nausea, fatigue, or pain on patients well-being, and they presume that PFS and good QOL go hand-in-hand; that is, that as long as patients maintain their response without progressing, that they are enjoying a good QoL.

That is not supported by the evidence in this study, the researchers said, which showed that global health-status/QOL, physical functioning, fatigue, and pain begin to deteriorate 2 to 3 months before progression of the underlying malignant disease.

However, better health-related QOL was associated with increased PFS, and both higher health-related QOL and physical functioning were associated with prolonged survival. Patient-reported outcome assessments are vital for understanding "individual needs and impairments, for prognostication, and for elucidating the impact of therapy on the various dimensions of QOL," the authors said.

Reference

Ludwig H, Pnisch W, Knop S, et al.Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population [published online September 26, 2019].Leuk. Lymphoma. doi: 10.1080/10428194.2019.1666381.

The rest is here:

Quality of Life Declines for Patients With Relapsed or Refractory MM Before Progression Appears - AJMC.com Managed Markets Network

SAN FRANCISCO Aspirin does not appear to reduce the risk of nonarteritic ischemic optic neuropathy development in men, according to data presented at the 2019 American Academy of Ophthalmology Meeting in San Francisco, CA.

Using multivariate Cox regression models, the researchers sought to determine the relationship between certain factors (ie, age, race, BMI, diabetes, smoking status, Charlson comorbidity index, hypertension, peripheral vascular disease, stroke, myocardial infarction, ischemic heart disease; aspirin, statin, warfarin, clopidogrel, sildenafil use) and a new diagnosis of nonarteritic ischemic optic neuropathy using data from the California Mens Health Study.

Results showed that among 45,281 participants who completed surveys between 2002 and 2006, 130 individuals developed nonarteritic ischemic optic neuropathy between 2002 and 2015. Factors that were associated with a new diagnosis of nonarteritic ischemic optic neuropathy included age (>60 years; hazard ratio [HR] 3.74; 95% CI 1.50 to 9.31) and long-term use of aspirin (HR 1.68; 95% CI 1.09 to 2.61).

Aspirin did not protect against a first episode of [nonarteritic ischemic optic neuropathy], the researchers concluded, adding that Aspirin users had a higher incidence of [nonarteritic ischemic optic neuropathy], most likely due to unaccounted-for confounders.

Reference

Modjtahedi, B S, et al. The Relationship Between Aspirin Use and NAION in Men. Poster number: PO252. The American Academy of Ophthalmology Meeting; October 12-15 2019.

More here:

Does Aspirin Protect Against Nonarteritic Ischemic Optic Neuropathy Development in Men? - Monthly Prescribing Reference

Global Cardiac Autonomic Neuropathy Treatment Market is a complete research study which portrays the present Cardiac Autonomic Neuropathy Treatment industry situations. Our latest study will provide the readers a complete knowledge about the past, present, and futuristic Cardiac Autonomic Neuropathy Treatment market aspects. In the beginning, elemental information stating the basic overview, product type, applications and Cardiac Autonomic Neuropathy Treatment development status is presented in this report. The key Cardiac Autonomic Neuropathy Treatment market trends which have led to the development of Cardiac Autonomic Neuropathy Treatment will drive useful market insights.

The key market factors which will influence the growth of Cardiac Autonomic Neuropathy Treatment industry like market share, key geographical regions, major key vendors are studied in-depth in this report. All the major Cardiac Autonomic Neuropathy Treatment regions and their contribution to the global market share are analyzed comprehensively. This report also studies the growth opportunities and the limiting factors of Cardiac Autonomic Neuropathy Treatment market. A detailed description related to supply chain structure, Cardiac Autonomic Neuropathy Treatment market size, consumer volume, and import/export scenario has been covered in this report. Analysis of major Cardiac Autonomic Neuropathy Treatment players, their company profile, market volume, Cardiac Autonomic Neuropathy Treatment production capacity, competitive landscape study will provide a complete picture of Cardiac Autonomic Neuropathy Treatment industry.

Request For Sample Report Before Buying (Use Corporate eMail ID to Get Higher Priority):https://market.us/report/cardiac-autonomic-neuropathy-treatment-market/request-sample

Major dominant companies are listed below:

PfizerRoche HoldingNovartisAmgenPrivi PharmaSilverline ChemicalsAnthem BiopharmaPraxis Pharmaceutical

Product Categories:

Solid OralInjectable

Product End-use Applications:

HospitalsCardiac CentersAmbulatory Surgical Centers

Top Geographical regions:

North America (US, Canada, and Mexico) Europe (Germany, France, UK, Russia, Italy, Spain, and Rest of Europe) Asia-Pacific (China, Japan, Korea, India, and Rest of Asia) Latin America (Brazil, Argentina, and the Rest of Latin America) The Middle East and Africa (GCC, South Africa, Israel, and Rest of MEA)

Inquire Before Buying Report (Use Corporate email ID to Get Higher Priority): https://market.us/report/cardiac-autonomic-neuropathy-treatment-market/ inquiry

Cardiac Autonomic Neuropathy Treatment market research provides answers to the following key questions:

-What will be the market size and the growth rate from 2019 to 2029?

-What are the key factors driving and retaining factors of Global Cardiac Autonomic Neuropathy Treatment Market?

-Who are the key market vendors and what are their strategies in the Global Cardiac Autonomic Neuropathy Treatment Market?

-What are the trending factors influencing the Cardiac Autonomic Neuropathy Treatment market shares in the Asia Pacific, North America, Latin America, Europe and Middle East and Africa?

-What trends, challenges, and barriers are influencing Cardiac Autonomic Neuropathy Treatment growth?

-What are the market opportunities and threats faced by the vendors in the Global Cardiac Autonomic Neuropathy Treatment Market?

Hence Cardiac Autonomic Neuropathy Treatment report evaluates all the crucial factors including the key players analysis, their business tactics and Cardiac Autonomic Neuropathy Treatment development expected during the forecast period. The analysis of top companies, their Cardiac Autonomic Neuropathy Treatment market revenue, consumer volume, emerging and existing Cardiac Autonomic Neuropathy Treatment market segments will help all the market players.

View Detailed Report Here:https://market.us/report/cardiac-autonomic-neuropathy-treatment-market/

Contact Us:Mr. Benni JohnsonMarket.us (Powered By Prudour Pvt. Ltd.)Tel: +1 718 618 4351.Email: [emailprotected]

Refer our Trending Reports:

Cold Box Casting Resin Market Forecast to 2029 | Profiling Global Players HA-International, Vesuvius Group and ASK ChemicalsThe Benefits Of Global Direct Drive Spindle Market to Rear Excessive Growth During 2029

Visit link:

Global Cardiac Autonomic Neuropathy Treatment Market Top Insights 2020:-Novartis, Pfizer and Roche Holding - Tech News Today

With a major research university right in our backyard, a strong military presence and innovative companies throughout the metro region, theres often a plethora of interesting science and technology news to be found in Southern Arizona. Heres a breakdown of the most interesting recent developments.

Smartphones and Depression. While a growing body of evidence connects technology addiction with depression and loneliness, its been unclear which leads to the other. Does constant smartphone usage make people depressed, or are depressed people more likely to spend time on their smartphones? A new study from researchers at the University of Arizonas College of Social and Behavioral Sciences found that smartphone dependency predicts higher reports of depressive symptoms and loneliness, rather than the other way around. The study examined 346 people aged 17-20 and the links between their smartphone engagement and psychological well-being. According to researcher Matthew Lapierre, the main takeaway from the study is smartphone dependency directly predicts later depressive symptoms. The study recommended health practitioners communicate with patients and parents about the links between smartphone use and psychological well-being.

Tech Jobs in Arizona. The Arizona Technology Council recently announced Arizonas tech sector is growing at a rate 40 percent faster than the U.S. overall. The announcement was in the Arizona Technology Councils quarterly impact report, which found the state has added 2,600 technology jobs since the beginning of the year. This brings the total number of technology-related jobs in Arizona to more than 180,000. These jobs tend to be high-paying, more than average Arizona wages, with an average annual salary of more than $80,000. Even more, these types of jobs are seeing consistent wage growth. This means Arizonas technology wages are now 20 percent higher than the national average. And although these STEM-related jobs generally require higher-education, nearly 30 percent of these STEM post-secondary graduates are staying in the state to work.

Quantum Sounds. A new paper published by researchers at the University of Arizonas Department of Materials Science and Engineering shows the possibility for acoustic waves to work in quantum information processing. In traditional computing, information is stored in binary (with a value of either 0 or 1), but in quantum computing, information can be stored in both positions at once (described as a superposition). While this massively increases the potential for computing, these entangled quantum bit states, or qubits, usually last less than a second before collapsing. Units of light are used in quantum mechanics for data processing, but the UA researchers are taking this a step further. In their paper The sound of Bell states they demonstrated for the first time that classical nonseparability can be applied to acoustic waves, not just light waves. Light lasers and single photons are part of the field photonics, but soundwaves fall under the umbrella of phononics, or the study of phonons, said Pierre Deymier, MSE department head. In addition to being stable, classically entangled acoustic waves are easy to interact with and manipulate.

Treating Chemotherapy Pain without Opioids. Researchers at UA Health Sciences are researching an effective, non-opioid treatment for neuropathic pain caused by chemotherapy. While chemotherapy remains one of the key treatments for cancer, it often causes damaging side effects, such as chemotherapy-induced peripheral neuropathy (CIPN), which is defined as damage to the nerves outside the brain and spinal cord, and is detected in 64 percent of cancer patients. In an attempt to create a less addictive treatment for CIPN, researchers are developing potent and selective T-type calcium channel antagonists. While initial results in pain management on rodent models have been promising, the research is still in its very early stages. According to professor of pharmacology Rajesh Khanna, this is the first step in developing non-opioid pain treatments for CIPN. This research is partially funded by a $340,000 grant from the National Institutes of Health as part of the Helping to End Addiction Long-Term initiative.

Link:

Connecting smartphones to depression | News - Inside Tucson Business

A research report on Peripheral Neuropathy Treatment Market 2019 Industry Research Report is being published by researchunt.com. This is a key document as far as the clients and industries are concerned to not only understand the competitive market status that exists currently but also what future holds for it in the upcoming period, i.e., between 2018 and 2025. It has taken the previous market status of 2013 2018 to project the future status. The report has categorized in terms of region, type, key industries, and application.

A sample of report copy could be downloaded by visiting the site:marketreports.co/global-peripheral-neuropathy-treatment-market-size-status-and-forecast-2019-2025/103336/#Free-Sample-Report

Global Peripheral Neuropathy Treatment revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of x.x% during 2018-2023.

Major Geographical Regions

The study report on Global Peripheral Neuropathy TreatmentMarket 2018 would cover every big geographical, as well as, sub-regions throughout the world. The report has focused on market size, value, product sales and opportunities for growth in these regions. The market study has analyzed the competitive trend apart from offering valuable insights to clients and industries. These data will undoubtedly help them to plan their strategy so that they could not only expand but also penetrate into a market.

The researchers have analyzed the competitive advantages of those involved in the industries or in the Peripheral Neuropathy Treatmentindustry. While historical years were taken as 2013 2017, the base year for the study was 2017. Similarly, the report has given its projection for the year 2018 apart from the outlook for years 2018 2025.

Key Players and Type

Like any other research material, the report has covered key geographical regions such as Europe, Japan, United States, India, Southeast Asia and Europe. Researchers have given their opinion or insights of value, product sales, and industry share besides availability opportunities to expand in those regions. As far as the sub-regions, North America, Canada, Medico, Australia, Asia-Pacific, India, South Korea, China, Singapore, Indonesia, Japan, Rest of Asia-Pacific, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, Russia, Central & South America, Middle East & Africa are included.

Major players in the report included are :

Types covered in thePeripheral Neuropathy Treatmentindustryare :

Applications covered in the report are :

Report Aims

The objective of the researchers is to find out sales, value, and status of the Peripheral Neuropathy Treatmentindustry at the international levels. While the status covers the years of 2013 17, the forecast is for the period 2018 25 that will enable market players to not only plan but also execute strategies based on the market needs.

Read Detailed Index of full Research Study at @marketreports.co/global-peripheral-neuropathy-treatment-market-size-status-and-forecast-2019-2025/103336/

The study wanted to focus on key manufacturers, competitive landscape, and SWOT analysis for Peripheral Neuropathy Treatmentindustry. Apart from looking into the geographical regions, the report concentrated on key trends and segments that are either driving or preventing the growth of the industry. Researchers have also focused on individual growth trend besides their contribution to the overall market.

There are 15 Chapters to display the GlobalPeripheral Neuropathy Treatmentmarket.

Sections 1. Industry Synopsis of Global Peripheral Neuropathy Treatment Market.

Sections 2. Peripheral Neuropathy Treatment Market Organization Producers analysis and Profiles.

Sections 3. Peripheral Neuropathy Treatment Market Size by Type and Application.

Sections 4. Global Peripheral Neuropathy Treatment Market 2018 Analysis by key traders.

Sections 5. Europe Peripheral Neuropathy Treatment Industry Report Development Status and Outlook.

Sections 6. Japan Peripheral Neuropathy Treatment Industry Report Development Status and Outlook.

Sections 7. Development Status and improvements of Peripheral Neuropathy Treatment Market in the United States.

Sections 8. Southeast Asia Peripheral Neuropathy Treatment Market Improvement Status and Outlook.

Sections 9. China Peripheral Neuropathy Treatment Market Report Development Status and Outlook.

Sections 10. India Peripheral Neuropathy Treatment Market Development Status and Outlook.

Sections 11. Peripheral Neuropathy Treatment Market Figure by Aoplications, areas, and Sorts (2018-2023)

Sections 12. Peripheral Neuropathy Treatment Market Factors Analysis.

Sections 13. Peripheral Neuropathy Treatment Market Dynamics.

Sections 14. Research Findings and Conclusions of Peripheral Neuropathy Treatment Market.

Sections 15. Appendix.

Browse Detailed TOC, Tables, Figures, Charts And Companies Mentioned In Peripheral Neuropathy Treatment Market Research Report At@marketreports.co/global-peripheral-neuropathy-treatment-market-size-status-and-forecast-2019-2025/103336/#Buying-Enquiry

View original post here:

Peripheral Neuropathy Treatment Market 2025: Topmost manufacturers With Size, Regions, Types, Major Drivers, Profits - TheFinanceTime

On the good news front in today's series, Stealth BioTherapeutics (MITO) and Alexion Pharmaceuticals (ALXN) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics' lead product candidate, which is being investigated in late stage clinical studies in three primary mitochondrial diseases - primary mitochondrial myopathy (PMM - an inherited disorder), Barth syndrome (enlarged & weakened heart) and Lebers hereditary optic neuropathy (LHON - an inherited vision loss), and in an earlier stage clinical study in dry age-related macular degeneration (dry-AMD).

It is good to see that small biopharma is still able to make quick bucks in short spans of time, isolated from the big economy. While there is undoubtedly a lot of pressure, and many portfolio and individual stocks have lost money, there are some that are doing well on science and fundamentals.

Today, I was reading an article about how isolationist tendencies are gripping countries the world over. The US is going its own unfathomable way; Britain is becoming an island again; the EU is like a robotic voice that continues running without power; and China is a sepulchre, boxed in, isolated, trying to buy its way out. I mention these things in an investment article because unlike 2008, the nature of the depression that is being predicted in some quarters is political. It is as macro as macro can get.

We discussed Stealth BioTherapeutics and PMM in July 2019 - and were not very enthusiastic about its prospects. However that may be, elamipretide is currently in phase 3 trial for PMM. Alexion's option will be exercised based on results from this study, which are expected by the end of 4Q-2019. These results are also important as phase 2 trials did not produce statistically significant data. If the drug is approved, Alexion and Stealth will co-promote the product in the U.S. on equal basis, while outside the U.S., Alexion will have exclusive rights for development and commercialization. Stealth will receive $30M upfront, which includes an option fee, equity investment and development funding. Alexion will make additional payments, including an option exercise fee, an additional equity investment, development funding and milestones if it exercises its option.

Stealth BioTherapeutics has the below pipeline in the lead indications for elamipretide.

(Image source: company website)

There are no therapies approved by the U.S. FDA or the European Medicines Agency (EMA) for the treatment of PMM. Stealth Bio has received Fast Track designation and Orphan Drug designation from the FDA for the development of elamipretide in this indication. Prevalence of PMM in the U.S. is estimated at 40,000. There are no therapies approved by the FDA or the EMA for treating Barth syndrome, which is estimated to affect between one in 300,000 to 400,000 births. The company has received Fast Track and Orphan Drug designation from the FDA for the development of elamipretide in this indication too. LHON has been diagnosed in approximately 10,000 individuals in the U.S. There are no therapies approved by the FDA for the treatment of LHON either, and Stealth BioTherapeutics has received Fast Track and Orphan Drug designation from the FDA for this indication as well. Dry-AMD is estimated to affect over 10 million individuals in the U.S., and it also does not have any therapies approved by the FDA or EMA.

Stealth BioTherapeutics is developing a Mitochondrial Carrier Technology (MCT) platform, which will utilize their proprietary compounds to deliver biologically active cargo to mitochondria. Preliminary data demonstrates the ability of the carrier compounds to direct the distribution of biologically active cargo to mitochondria. This approach shows possibilities for mitochondrial localization of small molecules, and may also have the potential to deliver peptides, proteins and oligonucleotides.

OncoSec Medical Inc. (ONCS) has entered into a strategic transaction with Grand Decade Developments Limited, a direct, wholly-owned subsidiary of China Grand Pharmaceutical (CGP) and Healthcare Holdings, and its affiliate, Sirtex Medical US Holdings. CGP and Sirtex are investing $30 million in OncoSec at $2.50/share, a 25% premium over the company's average share price over last 20 days. This would take the shareholding of CGP and Sirtex to 53% of OncoSec common shares. CGP can offer to buy the remaining shares within 12 months at the greater of $4.50 per share or 110% of the closing share price as on the prior date of such offer.

The present arrangement grants CGP "an exclusive license to develop, manufacture, commercialize, or exploit OncoSec's current and future products, including TAVO and OncoSec's new Visceral Lesion Applicator (VLA), in Greater China and 35 other Asian countries (the "territory")." CGP will pay up to 20% royalties on the net sales of such products in the territory, while "Sirtex will support and assist OncoSec with pre-marketing activities for TAVO and VLA in exchange for low single-digit royalties on TAVO and VLA net sales" outside the territory. With this transaction, OncoSec will have the funds needed to complete its ongoing pivotal clinical trial (KEYNOTE-695) of TAVO in combination with Merck's keytruda, in checkpoint-refractory metastatic melanoma, and the ongoing clinical trial (KEYNOTE-890) in chemo-refractory metastatic triple negative breast cancer. OncoSec anticipates filing for accelerated approval in the U.S. in 2020 after the completion of the KEYNOTE-695 trial. We discussed OncoSec's options back in December 2018, when the company was on the OTC market.

Amicus Therapeutics' (FOLD) shares were up in the premarket yesterday on preliminary Q3 results. Q3 sales of Galafold are expected to be around $48 million, above consensus of $45 million and 133% increase over previous year. Full-year revenue from Galafold is expected to be between $170 million and 180 million. Amicus expects to end the year with over $420 million cash, which should carry the company's operations well into 1H-2022.

Last week, the company presented additional positive data from the phase 1/2 study of AT-GAA in Pompe disease (GAA deficiency). The U.S. FDA previously granted Breakthrough Therapy Designation to AT-GAA for the treatment of late onset Pompe disease based on clinical efficacy results from this Phase 1/2 clinical study, including improvements in six-minute walk distance in late onset Pompe patients and comparison to natural history of treated patients. John F. Crowley, Chairman and CEO of Amicus, stated, Collectively these data continue to represent meaningful and durable improvements in functional outcomes, in addition to persistent reductions in key biomarkers of muscle damage and disease substrate." Further, he said that these results show that "AT-GAA has the potential to become the new standard of care for people living with Pompe." We analysed the company back in February 2019, and looks like the company is on track as we predicted.

Puma Biotechnology, Inc. (PBYI) is down further 6%, almost to near its 52-week low. Not much volume, though. Puma Biotechnology had recently raised the price of its breast cancer drug Nerlynx (neratinib) by 20%, which is being criticized by various influencers including Senator Bernie Sanders. Early this week, PBYI fell over 20% on the news of the exit of the company's chief commercial officer, Steven Lo, effective October 18. Steven Lo is taking over as CEO at Zosano Pharma. The stock was also downgraded at Goldman Sachs to "Sell" with a price target of $8.

Taro Pharmaceutical (TARO) has been hit with a patent infringement lawsuit by Aclaris Therapeutics (ACRS) together with Allergan plc (AGN). Taro had filed an ANDA with the U.S. FDA, seeking approval to manufacture and market a generic version of rhofade (oxymetazoline hydrochloride) cream 1%, before the expiry of the patents listed in the Orange Book, which are set to expire in 2035. Rhofade is an alpha1A adrenoceptor agonist, specifically indicated for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan developed and commercialized rhofade, which was approved by the U.S. FDA in January 2017. Allergan had acquired the drug as part of its 2011 acquisition of Vicept Therapeutics, Inc., which was established by some members of the current senior management at Aclaris. Aclaris acquired worldwide rights to rhofade from Allergan in November 2018, and its revenue will accrue to Aclaris from 4Q-2019.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Original post:

Stealth BioTherapeutics Does The Deal With Alexion, And Other Headlines: The Good, Bad And Ugly Of Biopharma - Seeking Alpha

Differences in lifestyles between socioeconomic groups are pretty pronounced. And now scientists have found a depressing new marker. Hidden in the sewage lies a clear difference between wealthy areas and poorer ones.

No, it's not gold in sewage this time. It's the remnants of the food we eat and the drugs we take that can paint a broader picture of how we live.

The study took place in Australia, where, over the course of the week of the national census in 2016, samples were taken from 22 wastewater treatment plant catchments, and examined for 42 biomarkers of things such as drugs and dietary metabolites.

These were later compared with census data on metrics such as rent prices, employment and education levels for each area.

"We show the extent to which consumption of chemicals such as opioids and illicit drugs are associated with sociodemographics. We also examine chemicals that reflect individuals' consumption of food components in wastewater and show that disparities in diet are associated with educational level," the researchers write in their paper.

"Our study shows that chemicals in wastewater reflect the social, demographic, and economic properties of the respective populations and highlights the potential value of wastewater in studying the sociodemographic determinants of population health."

What they found is sobering.

In wealthier areas, biomarkers were consistent with a better diet. Metabolites produced by the dietary intake of B vitamins (not supplements) were significantly more abundant in areas with higher rents, in agreement with previous research that found socioeconomically disadvantaged groups are less likely to meet nutritional guidelines.

Wealthier and better educated areas also had much higher concentrations of the biomarkers associated with eating a lot of fresh fruit and vegetables, as well as grains. All of these are associated with a healthier overall diet.

Interestingly, wealthier areas also had higher caffeine consumption. Coffee consumption is pretty universal, but is higher among better-off socioeconomic groups, especially ground coffee and espresso as opposed to instant coffee.

"We suggest," the researchers wrote, "that increased caffeine consumption in socioeconomically advantaged groups may reflect 1) greater financial freedom to indulge in caffeinated beverages (i.e., coffee) and/or 2) cultural institutionalisation of regular coffee drinking among advantaged and/or educated populations."

In lower socioeconomic areas, there were significantly higher levels of prescription medication for treating depression (desvenlafaxine, amitriptyline and citalopram), chronic pain (opioids such as methadone, codeine, tramadol and oxycodone, as well as pregabalin, for neuropathy) and blood pressure (atenolol).

"We considered antidepressants as a proxy for psychological distress," the researchers noted.

They were even able to link demographics with specific types of antidepressants. A higher proportion of labourers were prescribed desvenlafaxine. Amitriptyline was most often prescribed to people who didn't finish high school. And people taking citalopram tended to live alone, and were often separated or divorced.

We don't have to take the sewage at face value, either. All of these results appear to be consistent with other studies into the lifestyles of demographic groups.

Wastewater-based epidemiology is relatively new, and to date has been used primarily to study and monitor the use of drugs, both legal and illegal.

This study, the researchers said, shows that it can also be used as a means of studying the general health of human populations, and identifying areas that aren't doing so well.

"Our study shows that chemicals in wastewater reflect the social, demographic, and economic properties of the respective populations and highlights the potential value of wastewater in studying the sociodemographic determinants of population health," the researchers wrote.

The research has been published in PNAS.

Go here to read the rest:

There's a Depressing Difference Between The Sewage of Wealthy Areas And Poorer Ones - ScienceAlert

Neuropathy occurs in the feet or hands due to nerve damage. When a patient suffers from neuropathy, they can experience so-called neuropathic pain ranging from mild to severe and described as burning, pinpricks, or sudden shocks of electricity, as well as numbness, tingling, and weakness. The peripheral nervous system utilizes nerves to send messages to and from the central nervous system, which includes both the brain and spinal cord. When these peripheral nerves become damaged and their ability to transmit signals, neuropathy results. Although neuropathy is an encompassing diagnosis, there are many causes.

Diabetes can cause chronic neuropathy. High blood sugar levels can damage nerves, predominantly in the feet. This is why neuropathy more often occurs in people whose blood sugar is not under control than those who maintain low blood sugar levels. Diabetic neuropathy as a result of uncontrolled blood glucose levels can create irreversible damage to the nerves. When diabetes is under control, the amount of sugar in the blood remains at a safe level, thus reducing the risk of potential nerve damage.

Go here to see the original:

10 Causes of Neuropathy - Facty Health

Peripheral neuropathy is a condition that can affect the feet with a sensation of burning, tingling or numbness that may be periodic or constant. It is a frequent symptom of nerve trauma or pressure, vitamin B deficiency, alcoholism, diabetes, autoimmune diseases (such as HIV, lupus or rheumatoid arthritis) and diseases of the liver, kidneys and thyroid. Because peripheral neuropathy is involved in so many conditions, treatments vary widely.

Most drugs prescribed specifically for peripheral neuropathy will block or decrease the nerve sensations. They may include codeine, lidocaine, anti-seizure medications and antidepressants. Because some of these can cause dependency over long periods of time, other solutions may be tried first. Rubbing cremes on the feet or immersing them in warm water periodically may be an alternative.

The best treatment for peripheral neuropathy in the feet is to eliminate the cause. If the cause is clear -- abstain from alcohol, supplement vitamin B, brace joints to relieve pressure and so on -- those treatments should relieve the neuropathy. Many causes, however, are chronic and are not easily eliminated.

For those with chronic conditions causing their neuropathy, seeking treatment with a hypnotist trained in medical hypnosis may lead to more complete and convenient pain control than with oral pain relievers. Regular acupuncture treatments, perhaps with moxibustion, may also lead to a decreased pain sensation. In addition, t'ai chi ch'uan (taijiquan) may increase sensory perception for those with numbness in the feet.

Read this article:

The Best Treatment for Peripheral Neuropathy in Feet ...

Peripheral Neuropathy symptoms usually start with numbness, prickling or tingling in the toes or fingers. It may spread up to the feet or hands and cause burning, freezing, throbbing and/or shooting pain that is often worse at night.

The pain can be either constant or periodic, but usually the pain is felt equally on both sides of the bodyin both hands or in both feet. Some types of peripheral neuropathy develop suddenly, while others progress more slowly over many years.

Symptoms such as experiencing weakness or not being able to hold something, not knowing where your feet are, and experiencing pain that feels as if it is stabbing or burning in your limbs, can be common signs and symptoms of peripheral neuropathy.

The symptoms of peripheral neuropathy may depend on the kind of peripheral nerves that have been damaged.There are three types of peripheral nerves: motor, sensory and autonomic. Some neuropathies affect all three types of nerves, while others involve only one or two.

The majority of people, however, suffer from polyneuropathy, an umbrella term for damage involving many nerves at the same time.

Read the original post:

Peripheral Neuropathy Symptoms | Pain In Fingers, Toes, & Feet.

Peripheral Neuropathy

Peripheral neuropathy is a type of damage to the nervous system. Specifically, it is a problem with your peripheral nervous system. This is the network of nerves that sends information from your brain and spinal cord (central nervous system) to the rest of your body.

Peripheral neuropathy has many different causes. Some people inherit the disorder from their parents. Others develop it because of an injury or another disorder.

In many cases, a different type of problem, such as a kidney condition or a hormone imbalance, leads to peripheral neuropathy. One of the most common causes of peripheral neuropathy in the U.S. is diabetes.

There are more than 100 types of peripheral neuropathy, each with its own set of symptoms and prognosis. To help doctors classify them, they are often broken down into the following categories:

Motor neuropathy. This is damage to the nerves that control muscles and movement in the body, such as moving your hands and arms or talking.

Sensory neuropathy. Sensory nerves control what you feel, such as pain, temperature or a light touch. Sensory neuropathy affects these groups of nerves.

Autonomic nerve neuropathy. Autonomic nerves control functions that you are not conscious of, such as breathing and heartbeat. Damage to these nerves can be serious.

Combination neuropathies. You may have a mix of 2 or 3 of these other types of neuropathies, such as a sensory-motor neuropathy.

The symptoms of peripheral neuropathy vary based on the type that you have and what part of the body is affected. Symptoms can range from tingling or numbness in a certain body part to more serious effects such as burning pain or paralysis.

Muscle weakness

Cramps

Muscle twitching

Loss of muscle and bone

Changes in skin, hair, or nails

Numbness

Loss of sensation or feeling in body parts

Loss of balance or other functions as a side effect of the loss of feeling in the legs, arms, or other body parts

Emotional disturbances

Sleep disruptions

Loss of pain or sensation that can put you at risk, such as not feeling an impending heart attack or limb pain

Inability to sweat properly, leading to heat intolerance

Loss of bladder control, leading to infection or incontinence

Dizziness, lightheadedness, or fainting because of a loss of control over blood pressure

Diarrhea, constipation, or incontinence related to nerve damage in the intestines or digestive tract

Trouble eating or swallowing

Life-threatening symptoms, such as difficulty breathing or irregular heartbeat

The symptoms of peripheral neuropathy may look like other conditions or medical problems. Always see your healthcare provider for a diagnosis.

The symptoms and body parts affected by peripheral neuropathy are so varied that it may be hard to make a diagnosis. If your healthcare provider suspects nerve damage, he or she will take an extensive medical history and do a number of neurological tests to determine the location and extent of your nerve damage. These may include:

Depending on what basic tests reveal, your healthcare provider may want to do more in-depth scanning and other tests to get a better look at your nerve damage. Tests may include:

Usually a peripheral neuropathy cant be cured, but you can do a lot of things to prevent it from getting worse. If an underlying condition like diabetes is at fault, your healthcare provider will treat that first and then treat the pain and other symptoms of neuropathy.

In some cases, over-the-counter pain relievers can help. Other times, prescription medicines are needed. Some of these medicines include mexiletine, a medicine developed to correct irregular heart rhythms; antiseizure drugs, such as gabapentin, phenytoin, and carbamazepine; and some classes of antidepressants, including tricyclics such as amitriptyline.

Lidocaine injections and patches may help with pain in other instances. And in extreme cases, surgery can be used to destroy nerves or repair injuries that are causing neuropathic pain and symptoms.

Lifestyle choices can play a role in preventing peripheral neuropathy. You can lessen your risk for many of these conditions by avoiding alcohol, correcting vitamin deficiencies, eating a healthy diet, losing weight, avoiding toxins, and exercising regularly. If you have kidney disease, diabetes, or other chronic health condition, it is important to work with your healthcare provider to control your condition, which may prevent or delay the onset of peripheral neuropathy.

Even if you already have some form of peripheral neuropathy, healthy lifestyle steps can help you feel your best and reduce the pain and symptoms related to the disorder. Youll also want to quit smoking, not let injuries go untreated, and be meticulous about caring for your feet and treating wounds to avoid complications, such as the loss of a limb.

In some cases, non-prescription hand and foot braces can help you make up for muscle weakness. Orthotics can help you walk better. Relaxation techniques, such as yoga, may help ease emotional as well as physical symptoms.

Excerpt from:

Peripheral Neuropathy | Johns Hopkins Medicine

In this section:

Peripheral neuropathy is a type of nerve damage that typically affects the feet and legs and sometimes affects the hands and arms.

This type of neuropathy is very common. Up to one-half of people with diabetes have peripheral neuropathy.1,2

Over time, high blood glucose, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage your nerves and the small blood vessels that nourish your nerves, leading to peripheral neuropathy.

If you have peripheral neuropathy, your feet, legs, hands, or arms may feel

You may feel extreme pain in your feet, legs, hands, and arms, even when they are touched lightly. You may also have problems sensing pain or temperature in these parts of your body.

Symptoms are often worse at night. Most of the time, you will have symptoms on both sides of your body. However, you may have symptoms only on one side.

If you have peripheral neuropathy, you might experience:

Peripheral neuropathy can cause foot problems that lead to blisters and sores. If peripheral neuropathy causes you to lose feeling in your feet, you may not notice pressure or injuries that lead to blisters and sores. Diabetes can make these wounds difficult to heal and increase the chance of infections. These sores and infections can lead to the loss of a toe, foot, or part of your leg. Finding and treating foot problems early can lower the chances that you will develop serious infections.

This type of diabetes-related nerve damage can also cause changes to the shape of your feet and toes. A rare condition that can occur in some people with diabetes is Charcots foot, a problem in which the bones and tissue in your foot are damaged.

Peripheral neuropathy can make you more likely to lose your balance and fall, which can increase your chance of fractures and other injuries. The chronic pain of peripheral neuropathy can also lead to grief, anxiety, and depression.

Doctors diagnose peripheral neuropathy based on your symptoms, family and medical history, a physical exam, and tests. A physical exam will include a neurological exam and a foot exam.

If you have diabetes, you should get a thorough exam to test how you feel in your feet and legs at least once a year. During this exam, your doctor will look at your feet for signs of problems and check the blood flow and feeling, or sensation, in your feet by

Your doctor may also check if you can feel temperature changes in your feet.

Your doctor may perform tests to rule out other causes of nerve damage, such as a blood test to check for thyroid problems, kidney disease, or low vitamin B12 levels. If low B12 levels are found, your doctor will do additional tests to determine the cause. Metformin use is among several causes of low vitamin B12 levels. If B12 deficiency is due to metformin, metformin can be continued with B12 supplementation.

You can prevent the problems caused by peripheral neuropathy by managing your diabetes, which means managing your blood glucose, blood pressure, and cholesterol. Staying close to your goal numbers can keep nerve damage from getting worse.

If you have diabetes, check your feet for problems every day and take good care of your feet. If you notice any foot problems, call or see your doctor right away.

Remove your socks and shoes in the exam room to remind your doctor to check your feet at every office visit. See your doctor for a foot exam at least once a yearmore often if you have foot problems. Your doctor may send you to a podiatrist.

Doctors may prescribe medicine and other treatments for pain.

Your doctor may prescribe medicines to help with pain, such as certain types of

Although these medicines can help with the pain, they do not change the nerve damage. Therefore, if there is no improvement with a medicine to treat pain, there is no benefit to continuing to take it and another medication may be tried.

All medicines have side effects. Ask your doctor about the side effects of any medicines you take. Doctors dont recommend some medicines for older adults or for people with other health problems, such as heart disease.

Some doctors recommend avoiding over-the-counter pain medicines, such as acetaminophen and ibuprofen. These medicines may not work well for treating most nerve pain and can have side effects.

Your doctor may recommend other treatments for pain, including

Diabetes experts have not made special recommendations about supplements for people with diabetes. For safety reasons, talk with your doctor before using supplements or any complementary or alternative medicines or medical practices.

[1] Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136154.

[2] Izenberg A, Perkins BA, Bril V. Diabetic neuropathies. Seminars in Neurology. 2015;35(4):424430.

Link:

Peripheral Neuropathy | NIDDK

Treatment for peripheral neuropathymay includetreating any underlying cause or any symptoms you're experiencing.

Treatment may be more successfulfor certain underlying causes.For example,ensuringdiabetesis well controlled may help improve neuropathy or at least stop it getting worse.

There are many different possible causes of peripheral neuropathy, some of which can be treated in different ways. For example:

Some less common types of peripheral neuropathy may be treated with medication, such as:

However, the underlying cause may not always be untreatable.

You may also require medication to treat any nerve pain (neuropathic pain)you're experiencing.

Unlike most other types of pain, neuropathic pain doesn't usually get better with common painkillers, such as paracetamol andibuprofenand other medications areoften used.

These should usually be started at the minimum dose, with the dose gradually increased until you notice an effect, becausethe ideal dose for each person is unpredictable. Higher doses may bebetter at managing the pain, but are also more likely to cause side effects.

The most common side effects are tiredness, dizziness or feeling "drunk". If you get these, it may be necessary to reduce your dose. Don't drive or operate machineryif you experience drowsiness or blurred vision. You also may become more sensitive to the effects of alcohol.

The side effects should improve after a week or two as your body gets used to the medication. However, if your side effects continue, tell your GPas it may be possible to change to a different medication that suits you better.

Even if the first medication tried doesn't help, others may.

Many of these medications may also be used for treating other conditions, such as depression, epilepsy, anxiety or headaches. If you're given an antidepressant, this may treat pain even if you're not depressed.This doesn't mean your doctor suspects you're depressed.

The main medications recommended for neuropathic pain include:

There are also some additional medications that can be used to relieve pain in a specific area of the body or to relieve particularly severe pain for short periods. These are described below.

If your pain is confined to a particular area of your body and you can't, or would prefer not to,take the medications above, you may benefit from using capsaicin cream.

Capsaicin is the substance that makes chilli peppers hot and is thought to work in neuropathic pain by stopping the nerves sending pain messages to the brain.

A pea-sized amount of capsaicin cream is rubbed on the painful area of skin three or four times a day.

Side effects of capsaicin cream can include skin irritation and a burning sensation in the treated area when you first start treatment.

Don't use capsaicin cream on broken or inflamed skin and always wash your hands after applying it.

This is a large sticking plaster that contains a local anaesthetic. It's useful when pain affects only a small area of skin. It's stuck over the area of painful skin and the local anaesthetic is absorbed into the skin that's covered.

Tramadol is a powerful painkiller related to morphine that can be used to treat neuropathic pain that doesn't respond to other treatments your GP can prescribe.

Like all opioids, tramadol can be addictive if it's taken for a long time. It will usually only be prescribed for a short time.Tramadol can be useful to take at times when your pain is worse.

Common side effects of tramadol include:

In addition to treating pain, you may also require treatment to help you manage other symptoms you're experiencing as a result of peripheral neuropathy.

For example, if you have muscle weakness, you may need physiotherapyto learn exercises to improve your muscle strength. You may also need to wear splints to support weak ankles or use walking aids to help you get around.

Other problems associated with peripheral neuropathymay be treatable with medication, such as:

In some cases, you may need more invasive treatment, such as botulinum toxin injections for hyperhidrosisor urinary catheterisation if you have problems emptying your bladder.

Go here to see the original:

Peripheral neuropathy - Illnesses & conditions | NHS inform

Polyneuropathy (poly- + neuro- + -pathy) is damage or disease affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain.[3] It usually begins in the hands and feet and may progress to the arms and legs and sometimes to other parts of the body where it may affect the autonomic nervous system. It may be acute or chronic. A number of different disorders may cause polyneuropathy, including diabetes and some types of GuillainBarr syndrome.[4][5][6]

Polyneuropathies may be classified in different ways, such as by cause,[1] by presentation,[3] or by classes of polyneuropathy, in terms of which part of the nerve cell is affected mainly: the axon, the myelin sheath, or the cell body.[7][8]

Among the signs/symptoms of polyneuropathy, which can be divided (into sensory and hereditary) and are consistent with the following:[3]

The causes of polyneuropathy can be divided into hereditary and acquired and are therefore as follows:[1]

In regards to the pathophysiology of polyneuropathy, of course, the former depends on which polyneuropathy. For instance in the case of chronic inflammatory demyelinating polyneuropathy, one finds that it is a autoimmune disease. Here, T cells involvement has been demonstrated, while in terms of demyelination, antibodies alone are not capable.[16]

The diagnosis of polyneuropathies begins with a history and physical examination to ascertain the pattern of the disease process (such as-arms, legs, distal, proximal) if they fluctuate, and what deficits and pain are involved. If pain is a factor, determining where and how long the pain has been present is important, one also needs to know what disorders are present within the family and what diseases the person may have. Although diseases often are suggested by the physical examination and history alone, tests that may be employed include: electrodiagnostic testing, serum protein electrophoresis, nerve conduction studies, urinalysis, serum creatine kinase (CK) and antibody testing (nerve biopsy is sometimes done).[3][2]

Other tests may be used, especially tests for specific disorders associated with polyneuropathies, quality measures have been developed to diagnose patients with distal symmetrical polyneuropathy (DSP).[17]

In terms of the differential diagnosis for polyneuropathy one must look at the following:

In the treatment of polyneuropathies one must ascertain and manage the cause, among management activities are: weight decrease, use of a walking aid, and occupational therapist assistance. Additionally BP control in those with diabetes is helpful, while intravenous immunoglobulin is used for multifocal motor neuropathy.[3]

According to Lopate, et al., methylprednisolone is a viable treatment for chronic inflammatory demyelinative polyneuropathy (which can also be treated with intravenous immunoglobulin). The authors also indicate that prednisone has greater adverse effects in such treatment, as opposed to intermittent (high-doses) of the aforementioned medication.[3][21]

According to Wu, et al., in critical illness polyneuropathy supportive and preventive therapy are important for the affected individual, as well as, avoiding (or limiting) corticosteroids.[22]

See the original post:

Polyneuropathy - Wikipedia

Diabetic neuropathy is nerve damage that is caused by diabetes.

Nerves are bundles of special tissues that carry signals between your brain and other parts of your body. The signals

Types of diabetic neuropathy include the following:

Peripheral neuropathy is nerve damage that typically affects the feet and legs and sometimes affects the hands and arms.

Autonomic neuropathy is damage to nerves that control your internal organs. Autonomic neuropathy can lead to problems with your heart rate and blood pressure, digestive system, bladder, sex organs, sweat glands, eyes, and ability to sense hypoglycemia.

Focal neuropathies are conditions in which you typically have damage to single nerves, most often in your hand, head, torso, and leg.

Proximal neuropathy is a rare and disabling type of nerve damage in your hip, buttock, or thigh. This type of nerve damage typically affects one side of your body and may rarely spread to the other side. Proximal neuropathy often causes severe pain and may lead to significant weight loss.

If you have diabetes, your chance of developing nerve damage caused by diabetes increases the older you get and the longer you have diabetes. Managing your diabetes is an important part of preventing health problems such as diabetic neuropathy.

You are also more likely to develop nerve damage if you have diabetes and

Research also suggests that certain genes may make people more likely to develop diabetic neuropathy.

Over time, high blood glucose levels, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage your nerves. High blood glucose levels can also damage the small blood vessels that nourish your nerves with oxygen and nutrients. Without enough oxygen and nutrients, your nerves cannot function well.

Although different types of diabetic neuropathy can affect people who have diabetes, research suggests that up to one-half of people with diabetes have peripheral neuropathy.1,2 More than 30 percent of people with diabetes have autonomic neuropathy.2

The most common type of focal neuropathy is carpal tunnel syndrome, in which a nerve in your wrist is compressed. Although less than 10 percent of people with diabetes feel symptoms of carpal tunnel syndrome, about 25 percent of people with diabetes have some nerve compression at the wrist.2

Other focal neuropathies and proximal neuropathy are less common.

Your symptoms depend on which type of diabetic neuropathy you have. In peripheral neuropathy, some people may have a loss of sensation in their feet, while others may have burning or shooting pain in their lower legs. Most nerve damage develops over many years, and some people may not notice symptoms of mild nerve damage for a long time. In some people, severe pain begins suddenly.

Peripheral neuropathy can lead to foot complications, such as sores, ulcers, and infections, because nerve damage can make you lose feeling in your feet. As a result, you may not notice that your shoes are causing a sore or that you have injured your feet. Nerve damage can also cause problems with balance and coordination, leading to falls and fractures.

These problems may make it difficult for you to get around easily, causing you to lose some of your independence. In some people with diabetes, nerve damage causes chronic pain, which can lead to anxiety and depression.

Autonomic neuropathy can cause problems with how your organs work, including problems with your heart rate and blood pressure, digestion, urination, and ability to sense when you have low blood glucose.

To prevent diabetic neuropathy, it is important to manage your diabetes by managing your blood glucose, blood pressure, and cholesterol levels.

You should also take the following steps to help prevent diabetes-related nerve damage:

If you have diabetic neuropathy, you should manage your diabetes, which means managing your blood glucose, blood pressure, cholesterol levels, and weight to keep nerve damage from getting worse.

Foot care is very important for all people with diabetes, and its even more important if you have peripheral neuropathy. Check your feet for problems every day, and take good care of your feet. See your doctor for a neurological exam and a foot exam at least once a yearmore often if you have foot problems.

[1] Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136154.

[2] Izenberg A, Perkins BA, Bril V. Diabetic neuropathies. Seminars in Neurology. 2015;35(4):424430.

Follow this link:

What Is Diabetic Neuropathy? | NIDDK